The new Baxdrostat is significantly lowering blood pressure in people with blood pressure levels dangerously high, despite taking many available medications.
The study was conducted by researchers from the University of London in the United Kingdom, and its results were shown on August 30 during the European Society for Cardiology for the year 2025 held in the Spanish capital Merid, and the Yurrick Alert website was written about.
The experiment was performed led by Professor Brian Williams from the Institute of Cardiovascular Science at the University of London, and sponsored by Astrazinica, in which the pusrostate drug – which is taken in the form of tablets – was evaluated with the participation of approximately 800 patients in 214 clinics around the world.
The results of the experiment showed that after 12 weeks, the blood pressure of patients who took psdrosts (1 mg or 2 mg once a day in tablets) decreased by about 9-10 mm mercury compared to imaginary therapy, which is a sufficient decrease to reduce the risk of cardiovascular disease, and about 4 out of 10 patients have reached healthy blood pressure levels, compared to less than 2 out of every 10 patients who took imaginary therapy.
“The achievement of a decrease of approximately 10 mm Hg in systolic blood pressure using puscordos is interesting, as this level of decrease is associated with a significant decrease in the risk of heart attacks, strokes, heart failure and kidney disease.”
How does a pixrostat work?
About 1.3 billion people around the world suffer from high blood pressure, and in about half of the cases, the condition is not controlled or resistant to treatment, and these individuals face a much greater risk of heart attacks, strokes, kidney disease and early death.
Blood pressure is severely affected by the hormone aldosterone, which helps the kidneys regulate the balance of salts and water in the body, and the bodies of some people produce excess amounts of aldosterone, which causes salt and water retention in the body, and this disorder in the regulation of aldosterone leads to high blood pressure, which makes it difficult to control.
The European Assembly for high blood pressure for 2024 recommended targeted blood pressure less than 130/80 mm Hg, and before 2024 the target was 140/90 mm Hg.
The handling of the aldosterone disruption was a major research effort for decades, but achieving this was difficult until recently.
Paxrostat works by inhibiting the production of aldosterone, directly treating this factor that causes high blood pressure.
In patients with unspecified or treatment high blood pressure, adding 1 mg or 2 mg of puscarost once a day to the basic treatment for lowering blood pressure to noticeable decreases in systolic blood pressure, which lasted for up to 32 weeks without any unexpected safety results.